<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A large body of evidence indicates that genetic mutations, epigenetic changes, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp>, diet, and lifestyle are key risk factors for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Prevention of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> has long been considered a plausible approach for the population and individuals at high risk for developing this disease </plain></SENT>
<SENT sid="2" pm="."><plain>A significant effort has been made in the development of novel drugs for both prevention and treatment over the past two decades </plain></SENT>
<SENT sid="3" pm="."><plain>This review highlights recent advances in our understanding of the role of <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> prevention and adjuvant treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, we focus on the molecular mechanisms underlying the antitumor effects of these drugs in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The knowledge of how <z:chebi fb="1" ids="35472">anti-inflammatory agents</z:chebi> inhibit <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> formation and progression may provide a rationale for the development of more effective chemopreventive and chemotherapeutic agents with less toxicity </plain></SENT>
</text></document>